-+ 0.00%
-+ 0.00%
-+ 0.00%
Zhitong Finance App learned that on November 14, the new version of the catalogue will be officially implemented on January 1, 2027, and Velasipin® (eracycline hydrochloride tablets), a subsidiary of Genting Xinyao (01952.HK), and Yika® (injectable eracycline hydrochloride) passed the national health insurance negotiations and were included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2026)” for the first time. At the same time, it successfully renewed its contract for IgA nephropathy due to the therapeutic drug resistant to fukang® (budesonide enteric capsules) and remains on the catalogue.
Share
Listen to the news
Zhitong Finance App learned that on November 14, the new version of the catalogue will be officially implemented on January 1, 2027, and Velasipin® (eracycline hydrochloride for injection), a subsidiary of Genting Xinyao (01952.HK), passed the national health insurance negotiations and were included in the “National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue (2026)” for the first time. At the same time, it successfully renewed its contract for IgA nephropathy due to the therapeutic drug resistant to fukang® (budesonide enteric capsules) and remains on the catalogue.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending